Irofulven in Treating Patients With Persistent or Recurrent, Refractory Endometrial Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients who have
persistent or recurrent refractory endometrial cancer.